Navigation Links
Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
Date:12/9/2009

; the timing of completion of the Phase II pharmacokinetic study of Topical Interferon Alpha-2b for the minimum 12 patients; sufficiency of the Company's cash reserves and expected cash flow from operations; and other information in future periods, which statements can be identified by the use of forward-looking terminology such as "plans", "project", "expected", "intends"; "next", "anticipated", "developing", "will" or variations thereon. Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements and information involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors or assumptions have been applied in making forward-looking statements, including, but not limited to, assumptions regarding the patient recruitment rate for the ongoing Phase II pharmacokinetic study for Topical Interferon Alpha-2b (cervical dysplasia) and the sufficiency of data from the minimum 12 patients; the timely and successful completion of all activities leading up to the Company's planned IND and CTA filings for both L-DOS47 and Topical Interferon Alpha-2b (cervical dysplasia), including without limitation, GMP manufacturing; the timely provision of services and supplies by third parties; future revenue and costs; and the receipt of required regulatory approvals and necessary financing. Important risk factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, the Company's continuing need for additional capital, which may not be available in a timely manner or at all and which if not obtained will have a material adverse imp
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
4. Helix BioPharma Corp. Announces Fiscal 2009 Results
5. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
10. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)...  Luminex Corporation (NASDAQ: LMNX ) today announced ... Healthcare Conference to be held September 16 - 18, ... New York City . The investor ... Friday, September 18, 2015.  The presentation will be webcast live ... http://www.luminexcorp.com . Simply log on to the web at ...
(Date:9/4/2015)... India , September 4, 2015 ... Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) ... Technology and by Product - Global Forecast to 2020", ... to reach USD 2.5 Billion by 2020, growing at ... 2015 to 2020. Browse 139 Tables ...
(Date:9/4/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... Rodman & Renshaw 17 th Annual Global Investment ... New York City .  Dr. Michael Berelowitz ... on September 9, 2015. Presentation Details: ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
(Date:9/4/2015)... ... 04, 2015 , ... Many consumers are looking for a quick and convenient way to produce ... patent-pending K Med Cups provide a quick and simple way to brew a hot cup ... or cough. As a result, they enhance comfort and health. The invention features a novel ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference program for ... Florida October 9-10, 2015 at the Diplomat Resort & Spa has been announced ... and researchers at the top of their field and will be presenting sessions ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a 44.64 seconds scorcher ... victory in the men’s 400 meters final, with an impressive 44.89 seconds at the ... San Jose, Costa Rica in August 2015. The 44.64 time is a new NACAC ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The ... says are prophetic details involving the Pope’s upcoming trip to the United States. , Yisrayl ... what his role with the Vatican and society is. Yisrayl also provides the meaning of ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Friday night, Chicago ... hosting Generation Rescue’s A Night of Hope event supporting families affected by autism, raising ... Rowena and Joe Salas, joined together at the Oscar Swan Inn to support the ...
Breaking Medicine News(10 mins):Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2
... 28 ATS Medical Inc.,(Nasdaq: ATSI ), ... services, today announced that a total of 47 ... sutureless ATS 3f,Enable(TM) Aortic Bioprosthesis at seven investigative ... clinical trial phases. Currently,eight patients have surpassed the ...
... Anesthesia - With Virtually ... No Pain, Scarring or Bruising, ... the risky practices of traditional cosmetic surgery with new,treatment innovations ... introduced the first low-impact body sculpting,practice in the Northeast, headed ...
... Nov. 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI;,TSX: ... has formed a Special,Committee to review all strategic ... of three independent directors, has,appointed Morrison & Foerster, ... Committee. The Committee has been charged, among other ...
... Nonprofit Group is Awarded National Charity Seal, WASHINGTON, ... season, the Asthma and Allergy Foundation of America (AAFA),has ... Bureau,s (BBB),Wise Giving Alliance. The BBB National Charity Seal ... millions of Americans who donate to charities each year, ...
... 27 First Lady Laura Bush,today saluted the ... Overweight and Obesity Prevention Initiative, announced today at,the ... the,promotion of healthy weight for children., Mrs. ... an annual,HHS-hosted, cross-sector event that highlights new approaches ...
... SQUARE, Pa., Nov. 27 In its continued,educational ... Boiron,Laboratories disputes an editorial comment published in The ... its author has misinterpreted results of,clinical trials on ... features an editorial by Ben Goldacre on,the "Benefits ...
Cached Medicine News:Health News:ATS Medical Provides Update on Clinical Progress of ATS 3f Enable Aortic Bioprosthesis 2Health News:ATS Medical Provides Update on Clinical Progress of ATS 3f Enable Aortic Bioprosthesis 3Health News:ATS Medical Provides Update on Clinical Progress of ATS 3f Enable Aortic Bioprosthesis 4Health News:New Low-Impact Cosmetic Surgery Treatments Revolutionizing Industry 2Health News:New Low-Impact Cosmetic Surgery Treatments Revolutionizing Industry 3Health News:New Low-Impact Cosmetic Surgery Treatments Revolutionizing Industry 4Health News:QLT Board authorizes exploration of strategic alternatives to enhance near- to mid-term shareholder value 2Health News:QLT Board authorizes exploration of strategic alternatives to enhance near- to mid-term shareholder value 3Health News:Holiday Gift Arrives Early for Asthma Foundation 2Health News:HHS Launches Childhood Overweight and Obesity Prevention Initiative 2Health News:HHS Launches Childhood Overweight and Obesity Prevention Initiative 3Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 2Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 3
Provides access via PDA to determine whether imaging examinations are necessary based on symptons and which studies will generate the most information....
Provides quick access to information needed to make diagnoses and treatment decisions....
PDA formatted guide containing outlines and detailed information on the diagnosis and treatment of HIV infection and AIDS....
PDA application providing a complete guide for the diagnosis and management of electrolyte disorders....
Medicine Products: